Sign In

 Prof. Admire Dube

Position: Associate Professor of Pharmaceutics
Department: School of Pharmacy
Faculty: Faculty of Natural Science
Qualifications: B.Pharm (Zimbabwe), M.Pharm (UWC),
PhD (Monash)
Tel: 021 959 9253
Fax: 021-959-3407
Email: adube@uwc.ac.za
Research:

Biography

 Admire Dube is a National Research Foundation (NRF) Y1 rated scientist, and a United States National Institutes of Health (NIH) ‘Emerging Global Leader’ grant awardee. He possess a Ph.D. in Pharmaceutical Sciences (focussing on nanomedicine) from Monash University, Australia and post-doctoral training in nanomedicine and infectious diseases from the University at Buffalo, USA. He is a member of the Academy of Pharmaceutical Sciences of South Africa (APSSA) and a temporary advisor in one of the World Health Organization teams focused on medicines. In 2015 he was awarded the best research publication award in Pharmaceutics by the APSSA.

His research focusses on developing nanoparticles capable of stimulating the innate immune system to achieve Mycobacterium tuberculosis eradication. This can potentially enable the treatment of tuberculosis (TB) without use of conventional drugs to which the bacterium readily becomes resistant. He is the principal investigator on an NIH funded multi-institutional project to develop these nanoparticles. He has supervised or co-supervised 15 MSc and PhD students in nanomedicine and pharmaceutical sciences. He has published 20 research articles in international peer reviewed journals including 1 book chapter (accepted) and has over 20 national and international conference contributions. He is passionate to see Africa commercialize its first nanomedicine for an infectious disease, and in developing the next generation of innovative African pharmaceutical scientists.


Committees served on:

School of Pharmacy Higher Degrees Committee
UWC Senate Animal Research Committee

Publications

·     Tukulula, M., Gouveia, L., Paixao, P., Hayeshi, R., Naicker, B., Dube, A. (2018). Functionalization of PLGA Nanoparticles with 1,3-β-glucan Enhances the Intracellular Pharmacokinetics of Rifampicin in Macrophages. Pharmaceutical Research 35(6): 111.


·        Manyarara, T. E., Khoza, S., Dube, A., Maponga, C.C (2018). Formulation and characterization of a paediatric nanoemulsion dosage form with modified oral drug delivery system for improved dissolution rate of nevirapine. MRS Advances: 1-17.


·           Dube, A., Ebrahim, N. (2017). The nanomedicine landscape of South Africa, Nanotechnology Reviews, 6(4), 339-344.


·          Dube, A., Reynolds, JL. (2016). Modulation of Innate Immune Responses using Nanoparticles for Infectious Disease Therapy. Current Bionanotechnology, 2 (1), 60-65.


·        Tukulula, M., Hayeshi, R., Fonteh, P., Meyer, D., Ndamase, A., Madziva, M., Khumalo, V., Labuschagne, P., Naicker, B., Swai, H., Dube, A. (2015) Curdlan-Conjugated PLGA Nanoparticles Possess Macrophage Stimulant Activity and Drug Delivery Capabilities, Pharmaceutical Research 32, 2713-2726.


·       Chang, E.H., Harford, J.B., Eaton, M.A.W., Boisseau, P.M., Dube, A., Hayeshi, R., Swai, H., Lee, D.S. (2015) Nanomedicine: Past, present and future – A global perspective, Biophysical Research Communications 468, 511-517.


·                Melariri, P., Kalombo, L., Nkuna, P., Dube, A., Hayeshi, R., Ogutu, B., Gibhard, L., deKock, C., Smith, P., Wiesner, L., Swai, H. (2015) Oral lipid-based nanoformulation of tafenoquine enhanced bioavailability and blood stage antimalarial efficacy and led to a reduction in human red blood cell loss in mice, International Journal of Nanomedicine 10, 1493-1503.


·           Kutscher, H., Makita, F., DiTursi, S., Singh, A., Dube, A., Maponga, C.C., Morse, G.D., Reynolds, J. Macrophage Targeted Nanoparticles for Antiretroviral (ARV) Delivery. Journal of Personalized Nanomedicine, 1(2):40-48 (2015)


·         Chigumira, W., Maposa, P., Gadaga, L.L., Dube, A., Tagwireyi, D., Maponga, C.C. (2015) Preparation and Evaluation of Pralidoxime-Loaded PLGA Nanoparticles as Potential Carriers of the Drug across the Blood Brain Barrier, Journal of Nanomaterials 501 (2015) 692672.


·        Chifamba, J., Dube, A., Maponga, C. (2015) Ex-vivo penetration of nanometric ZnO and TiO2 across actinically damaged porcine skin: Development of an albinistic skin protection treatment, International Journal of Pharmaceutical Sciences and Research 6 (6).


·              Chifamba, J., Dube, A., Maponga, C. (2015) Investigation of in-vivo penetration and distribution of nanometric TiO2 in tropical albinistic skin by sequential adhesive tape stripping, International Journal of Pharmaceutical Sciences and Research 6 (2015) 4181.


·            Dube, A., Reynolds, J., Wing-Cheung, Law, Prasad, P.N., Morse, G.D. (2014) Multimodal nanoparticles that provide immunomodulation and intracellular drug delivery for infectious diseases. Nanomedicine: Nanotechnology, Biology and Medicine 10(4): 831-838.


·          Kadare, P., Maposa, P., Dube, A., Maponga, C.C. (2014) Encapsulation of Isoniazid in Chitosan-Gum Arabic and Poly (Lactic-Co-Glycolic Acid) PVA Particles to Provide a Sustained Release Formulation. Journal of Pharmaceutics and Pharmacology, 2014;S(1): 6.


·                Dube, A., Y. Lemmer, R. Hayeshi, M. Balogun, P. Labuschagne, H. Swai and L. Kalombo. (2013). State of the art and future directions in nanomedicine for tuberculosis. Expert Opinion on Drug Delivery 10(12), 1725-1734.


·              Dube, A., Nicolazzo, J.A., Larson, I. (2011).Chitosan nanoparticles enhance the plasma exposure of EGCG in mice through an enhancement in the intestinal stability of EGCG, European Journal of Pharmaceutical Sciences, 44(3), 422-426


·                Dube, A., Nicolazzo, J.A., Larson, I. (2011) Assessment of plasma concentrations of (−)-epigallocatechin gallate in mice following administration of a dose reflecting consumption of a standard green tea beverage, Food chemistry 128 (2011) 7-13.

·                Dube, A., Nicolazzo, J.A., Larson, I. (2010). Chitosan nanoparticles enhance the intestinal absorption of the green tea catechins (+)-catechin and (-)-epigallocatechin gallate, European Journal of Pharmaceutical Sciences, 41(2), 219-225


·            Dube, A., Ng, K., Nicolazzo, J.A., Larson, I. (2010). Effective use of reducing agents and nanoparticle encapsulation in stabilizing catechins in alkaline solution, Food Chemistry, 122(3), 662- 667


·         Dube, A., Manthata, L.N., Syce, J.A. (2007). The Design and Evaluation of Placebo Material for Crude Herbals: Artemisia afra Herb as a Model, Phytotherapy Research 21, 448-451.


·      Ramalapa, B., Semete-Makokotlela, B., Reynolds, J., Boury, F., Dube, A. Nanomedicines for the treatment of infectious diseases: Formulation, delivery and commercialization aspects. In Nanomedicine: Exploring the Potential for Nanotherapeutics. Ed: S. Farhangrazi & M. Moghimi. CRC Press-Taylor and Francis. (Accepted).

 

 

 

 ​

​​​

 

Networks

 • Council for Scientific and Industrial Research
• Collaboration with international universities: Wayne State University (USA), San Jose State University (USA), University at Buffalo (USA), University of Zimbabwe
• World Health Organization, Pre-qualification of medicines programme

UWC Supports Sustainability
© 2013 UWC | Disclaimer | Sign-in

Contact Centre

University of the Western Cape,
Robert Sobukwe Road,
Bellville, 7535,
Republic of South Africa

info@uwc.ac.za | +27 21 959 2911

Location